|
1
|
Pisani P, Parkin DM, Bray F and Ferlay J:
Estimates of the worldwide mortality from 25 cancers in 1990. Int J
Cancer. 83:18–29. 1999. View Article : Google Scholar
|
|
2
|
D’Amato RJ, Loughnan MS, Flynn E and
Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl
Acad Sci USA. 91:4082–4085. 1994.
|
|
3
|
Farris AB III, Dursun N, Dhanasekaran R,
Coban I, McIntosh EB, Adsay NV and Kim HS: Tumoral and angiogenesis
factors in hepatocellular carcinoma after locoregional therapy.
Pathol Res Pract. 208:15–21. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chao Y, Li CP, Chau GY, Chen CP, King KL,
Lui WY, Yen SH, Chang FY, Chan WK and Lee SD: Prognostic
significance of vascular endothelial growth factor, basic
fibroblast growth factor, and angiogenin in patients with
resectable hepatocellular carcinoma after surgery. Ann Surg Oncol.
10:355–362. 2003. View Article : Google Scholar
|
|
5
|
Jeng KS, Sheen IS, Wang YC, Gu SL, Chu CM,
Shih SC, Wang PC, Chang WH and Wang HY: Prognostic significance of
preoperative circulating vascular endothelial growth factor
messenger RNA expression in resectable hepatocellular carcinoma: a
prospective study. World J Gastroenterol. 10:643–646. 2004.
|
|
6
|
Poon RT, Ho JW, Tong CS, Lau C, Ng IO and
Fan ST: Prognostic significance of serum vascular endothelial
growth factor and endostatin in patients with hepatocellular
carcinoma. Br J Surg. 91:1354–1360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Folkman J: Tumor angiogenesis: therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eichholz A, Merchant S and Gaya AM:
Anti-angiogenesis therapies: their potential in cancer management.
Onco Targets Ther. 3:69–82. 2010.PubMed/NCBI
|
|
9
|
Yang JC, Haworth L, Sherry RM, Hwu P,
Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX and
Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular
endothelial growth factor antibody, for metastatic renal cancer. N
Engl J Med. 349:427–434. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cobleigh MA, Langmuir VK, Sledge GW,
Miller KD, Haney L, Novotny WF, Reimann JD and Vassel A: A phase
I/II dose-escalation trial of bevacizumab in previously treated
metastatic breast cancer. Semin Oncol. 30(5 Suppl 16): 117–124.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mayer RJ: Two steps forward in the
treatment of colorectal cancer. N Engl J Med. 350:2406–2408. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Desplancq D, Rinaldi AS, Stoessel A,
Sibler AP, Busso D, Oulad-Abdelghani M, Van Regenmortel MH and
Weiss E: Single-chain Fv fragment antibodies selected from an
intrabody library as effective mono- or bivalent reagents for in
vitro protein detection. J Immunol Methods. 369:42–50. 2011.
View Article : Google Scholar
|
|
13
|
Yamaguchi R, Yano H, Nakashima Y,
Ogasawara S, Higaki K, Akiba J, Hicklin DJ and Kojiro M: Expression
and localization of vascular endothelial growth factor receptors in
human hepatocellular carcinoma and non-HCC tissues. Oncol Rep.
7:725–729. 2000.PubMed/NCBI
|
|
14
|
Ochiumi T, Tanaka S, Oka S, Hiyama T, Ito
M, Kitadai Y, Haruma K and Chayama K: Clinical significance of
angiopoietin-2 expression at the deepest invasive tumor site of
advanced colorectal carcinoma. Int J Oncol. 24:539–547.
2004.PubMed/NCBI
|
|
15
|
Sun XD, Liu XE, Wu JM, Cai XJ, Mou YP and
Li JD: Expression and significance of angiopoietin-2 in gastric
cancer. World J Gastroenterol. 10:1382–1385. 2004.PubMed/NCBI
|
|
16
|
Zhang L, Yang N, Park JW, Katsaros D,
Fracchioli S, Cao G, O’Brien-Jenkins A, Randall TC, Rubin SC and
Coukos G: Tumor-derived vascular endothelial growth factor
up-regulates angiopoietin-2 in host endothelium and destabilizes
host vasculature, supporting angiogenesis in ovarian cancer. Cancer
Res. 63:3403–3412. 2003.
|
|
17
|
Sfiligoi C, de Luca A, Cascone I, Sorbello
V, Fuso L, Ponzone R, Biglia N, Audero E, Arisio R, Bussolino F,
Sismondi P and De Bortoli M: Angiopoietin-2 expression in breast
cancer correlates with lymph node invasion and short survival. Int
J Cancer. 103:466–474. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Glade Bender J, Cooney EM, Kandel JJ and
Yamashiro DJ: Vascular remodeling and clinical resistance to
antiangiogenic cancer therapy. Drug Resist Updat. 7:289–300.
2004.PubMed/NCBI
|
|
19
|
Wong MP, Chan SY, Fu KH, Leung SY, Cheung
N, Yuen ST and Chung LP: The angiopoietins, tie2 and vascular
endothelial growth factor are differentially expressed in the
transformation of normal lung to non-small cell lung carcinomas.
Lung Cancer. 29:11–22. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang ZL, Liu ZS and Sun Q: Significance
of angiopoietins, Tie2 and vascular endothelial growth factor in
the angiogenesis and development of hepatocellular carcinoma. World
J Gastroenterol. 12:4241–4245. 2006.PubMed/NCBI
|
|
21
|
Maisonpierre PC, Suri C, Jones PF,
Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J,
Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN and
Yancopoulos GD: Angiopoietin-2, a natural antagonist for Tie2 that
disrupts in vivo angiogenesis. Science. 277:55–60. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dai H, Gao H, Zhao X, Dai L, Zhang X, Xiao
N, Zhao R and Hemmingsen SM: Construction and characterization of a
novel recombinant single-chain variable fragment antibody against
White Spot Syndrome Virus from shrimp. J Immunol Methods.
279:267–275. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Barbas CF III, Burton DR, Scott JK and
Silverman GJ: Phage Display: A Laboratory Manual. Cold Spring
Harbor Laboratory Press; Cold Spring Harbor: 2001
|
|
24
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis - correlation in invasive
breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gale NW and Yancopoulos GD: Growth factors
acting via endothelia cell-spcific receptor tyrosine kinases:
VEGFs, angiopoietins, and ephrins in vascular development. Genes
Dev. 13:1055–1066. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Davis S, Aldrich TH, Jones PF, Acheson A,
Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre
PC and Yancopoulos GD: Isolation of angiopoietin-1, a ligand for
the TIE2 receptor, by secretion-trap expression cloning. Cell.
87:1161–1169. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Saharinen P, Bry M and Alitalo K: How do
angiopoietins Tie in with vascular endothelial growth factors? Curr
Opin Hematol. 17:198–205. 2010.PubMed/NCBI
|
|
28
|
Pham VN, Roman BL and Weinstein BM:
Isolation and expression analysis of three zebrafish angiopoietin
genes. Dev Dyn. 221:470–474. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hata K, Udagawa J, Fujiwaki R, Nakayama K,
Otani H and Miyazaki K: Expression of angiopoietin-1,
angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum
and in ovarian cancer. Oncology. 62:340–348. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mitsuhashi N, Shimizu H, Ohtsuka M,
Wakabayashi Y, Ito H, Kimura F, Yoshidome H, Kato A, Nukui Y and
Miyazaki M: Angiopoietins and Tie-2 expression in angiogenesis and
proliferation of human hepatocellular carcinoma. Hepatology.
37:1105–1113. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sugimachi K, Tanaka S, Taguchi K, Aishima
S, Shimada M and Tsuneyoshi M: Angiopoietin switching regulates
angiogenesis and progression of human hepatocellular carcinoma. J
Clin Pathol. 56:854–860. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Suri C, Jones PF, Patan S, Bartunkova S,
Maisonpierre PC, Davis S, Sato TN and Yancopoulos GD: Requisite
role of angiopoietin-1, a ligand for the TIE2 receptor, during
embryonic angiogenesis. Cell. 87:1171–1180. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Teichert-Kuliszewska K, Maisonpierre PC,
Jones N, Campbell AI, Master Z, Bendeck MP, Alitalo K, Dumont DJ,
Yancopoulos GD and Stewart DJ: Biological action of angiopoietin-2
in a fibrin matrix model of angiogenesis is associated with
activation of Tie2. Cardiovasc Res. 49:659–670. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang J, Wu K, Zhang D, Tang H, Xie H, Hong
L, Pan Y, Lan M, Hu S, Ning X and Fan D: Expression and clinical
significances of angiopoietin-1, -2 and Tie2 in human gastric
cancer. Biochem Biophy Res Commun. 337:386–393. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nakayama T, Hatachi G, Wen CY, Yoshizaki
A, Yamazumi K, Niino D and Sekine I: Expression and significance of
Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in
colorectal adenocarcinoma: Immunohistochemical analysis and
correlation with clinicopathological factors. World J
Gastroenterol. 11:964–969. 2005. View Article : Google Scholar
|
|
36
|
Wada H, Nagano H, Yamamoto H, Yang Y,
Kondo M, Ota H, Nakamura M, Yoshioka S, Kato H, Damdinsuren B, Tang
D, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Sakon
M, Dono K, Wakasa K and Monden M: Expression pattern of angiogenic
factors and prognosis after hepatic resection in hepatocellular
carcinoma: importance of angiopoietin-2 and hypoxia-induced
factor-1 alpha. Liver Int. 26:414–423. 2006. View Article : Google Scholar
|
|
37
|
Jain RK: Normalization of tumor
vasculature: an emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Smith GP: Filamentous fusion phage: novel
expression vectors that display cloned antigens on the virion
surface. Science. 228:1315–1317. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Smith GP and Petrenko VA: Phage Display.
Chem Rev. 97:391–410. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bratkovic T: Progress in phage display.
Cell Mol Life Sci. 67:749–767. 2010. View Article : Google Scholar
|
|
41
|
Huston JS, Levinson D, Mudgett-Hunter M,
Tai MS, Novotný J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E,
Crea R, et al: Protein engineering of antibody binding sites:
recovery of specific activity in an anti-digoxin single-chain Fv
analogue produced in Escherichia coli. Proc Natl Acad Sci
USA. 85:5879–5883. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rao Y, Zhong L, Liao T, Jin S, Wang Y,
Song B, Li J, Zhang X, Hemmingsen SM, Xu Y and Dai H: Novel
recombinant monoclonal antibodies for vitellogenin assays in
cyprinid fish species. Dis Aquat Organ. 93:83–91. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lobov IB, Brooks PC and Lang RA:
Angiopoietin-2 displays VEGF-dependent modulations of capilliary
structure and endothelial cell survival in vivo. Proc Natl Acad Sci
USA. 99:11205–11210. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ji Y, Wang Z, Li Z, Li K, Le X and Zhang
T: Angiotensin II induces angiogenic factors production partly via
AT1/JAK2/STAT3/SOCS3 signaling pathway in MHCC97H cells. Cell
Physiol Biochem. 29:863–874. 2012. View Article : Google Scholar
|
|
45
|
Imai N, Hashimoto T, Kihara M, Yoshida S,
Kawana I, Yazawa T, Kitamura H and Umemura S: Roles for host and
tumor angiotensin II type 1 receptor in tumor growth and
tumor-associated angiogenesis. Lab Invest. 87:189–198. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
White RR, Shan S, Rusconi CP, Shetty G,
Dewhirst MW, Kontos CD and Sullenge BA: Inhibition of rat corneal
angiogenesis by a nuclease-resistant RNA aptamer specific for
angiopoietin-2. Proc Natl Aead Sci USA. 100:5028–5033. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li Y, Tang Y, Ye L, Liu B, Liu K, Chen J
and Xue Q: Establishment of a hepatocellular carcinoma cell line
with unique metastatic characteristics through in vivo selection
and screening for metastisis-related genes through cDNA microarray.
J Cancer Res Clin Oncol. 129:43–51. 2003.
|
